GLPwatch
Papers (10410)
Page 141 of 174, ranked by citation count.
- Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2.
- "Why you should (not) use semaglutide?": A critical discourse analysis on health professionals' videos of semaglutide for weight loss on Douyin.
- [Lixisenatide (Lyxumia), subcutaneous].
- Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip.
- A review regarding the article 'Semaglutide and heart failure: Updated meta-analysis'.
- In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
- Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique.
- Semaglutide and Cardiovascular Outcomes.
- Semaglutide in Patients Undergoing Anesthesia for Otolaryngologic Procedures.
- Tirzepatide Outperforms Dulaglutide for Type 2 Diabetes Control.
- Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review.
- Effect of Peptide Drug Liraglutide Nano-Formulation Combined with Sodium-Glucose Cotransporter-2 Inhibitor on Blood Lipids in Patients with Type 2 Diabetes.
- Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.
- Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply.
- Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.
- Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
- Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.
- Is global interest in fasting, intermittent fasting and the liver shifting?
- GLP-1 and GIP Changes after Sleeve Gastrectomy and Weight Regain in Adolescents. Do we need a Boost?
- Microbial expression of Exendin-4 analog and its efficacy in mice model.
- Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes.
- RGB Trichromatic Whiteness Assessment of Bio Analytical Chromatographic Tool Using Fluorescence for Quantitation of Semaglutide: Application to Pharmaceutical Preparations and Spiked Plasma.
- Unremitting Nausea Due to Lurasidone After Semaglutide Initiation.
- Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study.
- Orforglipron in type 2 diabetes mellitus and obesity: an overview.
- Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.
- Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission.
- 2017 New Drug Update.
- Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels.
- Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.
- The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.
- [For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?]
- Sixty seconds on . . . semaglutide.
- [Severe gastroparesia associated with the use of GLP-1 receptor agonists for weight loss].
- GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder.
- Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.
- [Natriuretic effect of exenatide: high efficacy and site of action].
- Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes.
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.
- Mechanisms of efficacy of drug therapy in type 2 diabetes: the role of microbiomes.
- Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease.
- Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
- The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.
- Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.
- Engineering Marker-Free Lettuce Chloroplast Genome to Express Functional Glucagon-Like Peptide-1 Receptor Agonists Exenatide and Lixisenatide.
- Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.
- Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.
- Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
- Tirzepatide-Induced Liver Injury: A Rare Complication.
- Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance.
- Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.
- Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective.
- Semaglutide: A New Medical Swiss Army Knife?
- Semaglutide and Cardiovascular Outcomes. Reply.
- Management of Obesity in Psoriasis Consultations.
- ▾ Liraglutide for weight management.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
- Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.